Results 151 to 160 of about 45,933 (222)

LRRC32 Mediates Resistance to Everolimus in Hormone Receptor-Positive, HER2-Negative Breast Cancer. [PDF]

Cancer Manag Res
Wang L, Chen X, Li X, Wang Y, Shen R.
europepmc   +1 more source

Chemoimmunotherapy‐associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

HemaSphere, Volume 10, Issue 10, October 2026.
Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe‐Paganon, Filip Garbicz, Ruben Carrasco, John Hatcher, Andres Ramirez‐Gamero, Dominic Pizzarella, Amanda Kofides, Shirong Liu, Hao Sun, Xia Liu, María L. Guerrera, Andrew R. Branagan, Gottfried von Keudell, Shayna R. Sarosiek, Jorge J. Castillo, Zachary R. Hunter, Steven P. Treon   +18 more
wiley   +1 more source

Controversies in NEN: An ENETS position statement on the role of liver transplantation (LT) in patients with advanced small‐intestinal and pancreatic NETs

Journal of Neuroendocrinology, Volume 38, Issue 10, October 2026.
Abstract Liver transplantation (LT) may offer survival or symptomatic benefit for highly selected patients with advanced, well‐differentiated small‐intestinal or pancreatic neuroendocrine tumours and unresectable liver‐dominant metastases. However, its role remains controversial, as LT is rarely curative, recurrence is common, and benefits must be ...
Peter Stålberg, Mairéad G. McNamara, Simona Grozinsky‐Glasberg, Andreas Pascher, Beata Kos‐Kudla, Timm Denecke, Nehara Begum, Wendy Martin, Stephanie Alband, Clarisse Dromain, Raj Srirajaskanthan, Eric Baudin   +11 more
wiley   +1 more source

Long-Term Monitoring of Everolimus Concentrations in Routine Clinical Practice: Evaluation of Patient Percentiles as Quality Indicator and Impact of Analytical Method Change. [PDF]

Pharmaceuticals (Basel)
Larsson AO, Hamberg AK, Eriksson MB.
europepmc   +1 more source

Probable everolimus-associated severe colitis with hematochezia in a patient with metastatic hormone receptor-positive, HER2-negative breast cancer: a case report. [PDF]

Front Pharmacol
Fatayer A, Qupp SK, Morcos J, Zyadah Z, Alresheq A, Bushnaq J, Qubaja M, Laban OA.   +7 more
europepmc   +1 more source

Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers

, 2015
Karen Thudium,1 Jorge Gallo,2 Emmanuel Bouillaud,2 Carolin Sachs,2 Simantini Eddy,1 Wing Cheung1 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Novartis Pharma AG, Basel, Switzerland Background: The mammalian target of rapamycin (mTOR ...
Cheung W, Thudium K, Eddy S, Gallo J, Sachs C, Bouillaud E   +5 more
core  

Comparative Effects of Pairwise Combinations of Carboplatin, Everolimus, and Astaxanthin on Cell Viability, Migration, and Inflammatory Biomarkers in SKOV3 Ovarian Cancer Cells. [PDF]

Int J Mol Sci
Karalok MH, Biltekin B, Karci E, Uzun H.
europepmc   +1 more source

Two-Year Clinical Outcomes of Contemporary Drug-Eluting Stents Grouped by Eluted Limus Agent: A Retrospective Cohort Study. [PDF]

J Clin Med
Joo D, Byoun JT, Cho JY, Jo S, Yun KH.
europepmc   +1 more source

Systemic Everolimus Does Not Block the Incubation of Methamphetamine-Craving: A Dose-Response Study. [PDF]

Addict Biol
Cano FJ, Smith KE, Stuemke K, Jotwani A, Lassers E, Nelson HM, Adler SD, Huerta Sanchez LL, Denning CJE, Davantes SM, Ibarra CA, Kippin TE, Szumlinski KK.   +12 more
europepmc   +1 more source

Everolimus Attenuates Salicylate-Induced Tinnitus-Like Behavior and Auditory Cortical Hyperexcitability. [PDF]

Drug Des Devel Ther
Fan B, Liu Y, Cao W, Li T, Li M, Zhang K, Ma F.   +6 more
europepmc   +1 more source